Treating disease progression with osimertinib in EGFR-mutated non-small-cell lung cancer: novel targeted agents and combination strategies

Authors:

Abstract
No abstract available
Funding Information
  • Roche
  • Pfizer
  • Celgene
  • AstraZeneca
  • Meso Scale Diagnostics
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Novartis

This publication has 105 references indexed in Scilit: